BMO Capital reiterates Outperform rating on Eli Lilly stock at $840 price target
PositiveFinancial Markets

BMO Capital has reaffirmed its Outperform rating on Eli Lilly's stock, setting a price target of $840. This endorsement reflects confidence in Eli Lilly's growth potential and market position, which is significant for investors looking for promising opportunities in the pharmaceutical sector.
— Curated by the World Pulse Now AI Editorial System